Total Payments
$14,183
2024 Payments
$2,614
Companies
55
Transactions
616
Medicare Patients
3,392
Medicare Billing
$330,463
Payment Breakdown by Category
Food & Beverage$9,881 (69.7%)
Research$1,600 (11.3%)
Other$1,196 (8.4%)
Consulting$1,162 (8.2%)
Education$343.34 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,881 | 586 | 69.7% |
| Unspecified | $1,600 | 3 | 11.3% |
| Long term medical supply or device loan | $1,196 | 12 | 8.4% |
| Consulting Fee | $1,162 | 1 | 8.2% |
| Education | $343.34 | 14 | 2.4% |
Payments by Type
General
$12,583
613 transactions
Research
$1,600
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,582 | 88 | $0 (2024) |
| PFIZER INC. | $2,557 | 82 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,804 | 35 | $0 (2024) |
| Genentech USA, Inc. | $733.84 | 53 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $673.09 | 43 | $0 (2024) |
| Merck Sharp & Dohme LLC | $647.40 | 31 | $0 (2024) |
| Celgene Corporation | $561.84 | 21 | $0 (2024) |
| Amgen Inc. | $409.32 | 27 | $0 (2023) |
| Eisai Inc. | $402.58 | 17 | $0 (2024) |
| Janssen Biotech, Inc. | $352.40 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,614 | 83 | Novartis Pharmaceuticals Corporation ($1,450) |
| 2023 | $1,151 | 61 | Janssen Biotech, Inc. ($137.53) |
| 2022 | $1,257 | 51 | PFIZER INC. ($418.62) |
| 2021 | $412.94 | 20 | AstraZeneca Pharmaceuticals LP ($73.72) |
| 2020 | $1,861 | 41 | PFIZER INC. ($1,351) |
| 2019 | $1,685 | 118 | Novartis Pharmaceuticals Corporation ($253.14) |
| 2018 | $2,018 | 122 | E.R. Squibb & Sons, L.L.C. ($281.31) |
| 2017 | $3,183 | 120 | AstraZeneca Pharmaceuticals LP ($1,222) |
All Payment Transactions
616 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.40 | General |
| 12/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: DESMOID TUMORS | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $20.97 | General |
| Category: Oncology | ||||||
| 12/04/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.08 | General |
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/14/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: Immunology | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $33.48 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,600 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 851 | 1,402 | $215,776 | $100,950 |
| 2022 | 5 | 689 | 1,051 | $137,307 | $63,843 |
| 2021 | 9 | 904 | 1,552 | $198,782 | $93,318 |
| 2020 | 9 | 948 | 1,584 | $190,151 | $72,352 |
Total Patients
3,392
Total Services
5,589
Medicare Billing
$330,463
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 155 | 280 | $54,080 | $28,773 | 53.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 191 | 382 | $52,056 | $26,839 | 51.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 94 | 135 | $34,563 | $14,801 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 79 | 146 | $29,501 | $11,285 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 186 | 227 | $17,146 | $10,385 | 60.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 75 | 108 | $14,452 | $5,285 | 36.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 13 | $7,903 | $1,745 | 22.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 12 | $3,872 | $1,013 | 26.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 48 | 99 | $2,203 | $823.83 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 118 | 165 | $30,876 | $17,134 | 55.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 126 | 230 | $29,782 | $15,565 | 52.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 95 | $23,057 | $10,457 | 45.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 159 | 207 | $14,444 | $8,019 | 55.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 98 | $18,410 | $6,928 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 79 | 98 | $13,906 | $4,414 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 12 | $3,735 | $895.70 | 24.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 64 | 146 | $3,097 | $430.35 | 13.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 147 | 293 | $36,196 | $21,131 | 58.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 273 | 399 | $24,594 | $17,288 | 70.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 78 | 155 | $27,040 | $16,573 | 61.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 75 | 102 | $26,201 | $11,775 | 44.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 132 | $25,521 | $10,071 | 39.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 102 | 174 | $25,320 | $9,010 | 35.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 37 | $10,790 | $2,903 | 26.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $9,373 | $2,486 | 26.5% |
About Dr. Steven Corso, MD
Dr. Steven Corso, MD is a Hematology & Oncology healthcare provider based in Spartanburg, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1407858467.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Corso, MD has received a total of $14,183 in payments from pharmaceutical and medical device companies, with $2,614 received in 2024. These payments were reported across 616 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($9,881).
As a Medicare-enrolled provider, Corso has provided services to 3,392 Medicare beneficiaries, totaling 5,589 services with total Medicare billing of $330,463. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Spartanburg, SC
- Active Since 06/02/2005
- Last Updated 12/14/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1407858467
Products in Payments
- IBRANCE (Drug) $2,018
- KISQALI (Drug) $1,689
- LYNPARZA (Drug) $1,232
- KEYTRUDA (Biological) $570.55
- IMBRUVICA (Drug) $427.63
- OPDIVO (Biological) $427.37
- Lenvima (Drug) $344.44
- Revlimid (Drug) $225.69
- Trodelvy (Drug) $211.54
- TASIGNA (Drug) $198.66
- Perjeta (Biological) $187.47
- TAGRISSO (Drug) $178.13
- XTANDI (Drug) $173.90
- Avastin (Biological) $160.61
- PIQRAY (Drug) $140.28
- JAKAFI (Drug) $126.13
- PROMACTA (Drug) $124.83
- Imbruvica (Drug) $120.84
- CALQUENCE (Drug) $118.66
- Neulasta (Biological) $112.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Spartanburg
Ki Chung, Md, MD
Hematology & Oncology — Payments: $80,327
Hematology & Oncology $80,327
James Bearden, Md, MD
Hematology & Oncology — Payments: $12,982
Hematology & Oncology $12,982
Dr. Kim Hont Yee, Md, MD
Hematology & Oncology — Payments: $12,245
Hematology & Oncology $12,245
Dr. Abderrahim Khomani, M.d, M.D
Hematology & Oncology — Payments: $9,748
Hematology & Oncology $9,748
Mr. Leonard Schutz, Md, Facp, MD, FACP
Hematology & Oncology — Payments: $4,746
Hematology & Oncology $4,746
Dr. Samuel Adediran, M.d.,, M.D.,
Hematology & Oncology — Payments: $3,434
Hematology & Oncology $3,434